List of Articles (2017-2018)


  1. “Mortality and morbidity in patients receiving encainide, flecainide, or placebo” (CAST). N Engl J Med. 1991 Mar 21;324(12):781-8. [post – Week 11] [free full text]
  2. “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure” (SOLVD). N Engl J Med. 1991 Aug 1;325(5):293-302. [post – Week 28] [free full text]
  3. “Effect of carvedilol on survival in severe chronic heart failure.” (COPERNICUS). N Engl J Med. 2001 May 31;344(22):1651-8. [post – Week 16] [free full text]
  4. “Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation” (CHADS2). JAMA. 2001 Jun 13;285(22):2864-70. [post – Week 20] [free full text]
  5. “Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).” JAMA. 2002 Dec 18;288(23):2981-97. [post – Week 29] [free full text]
  6. “A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation” (AFFIRM). N Engl J Med. 2002 Dec 5;347(23):1825-33. [post – Week 2] [free full text]
  7. “Intensive versus moderate lipid lowering with statins after acute coronary syndromes” (PROVE IT-TIMI 22). N Engl J Med. 2004 Apr 8;350(15):1495-504. [post – Week 41] [free full text]
  8. “Optimal Medical Therapy with or without PCI for Stable Coronary Disease” (COURAGE). N Engl J Med. 2007 Apr 12;356(15):1503-16. [post – Week 6] [free full text]
  9. “Ticagrelor versus clopidogrel in patients with acute coronary syndromes” (PLATO). N Engl J Med. 2009 Sep 10;361(11):1045-57. [post – Week 34] [free full text]
  10. “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.” Chest. 2010 Nov;138(5):1093-100 [post – Week 48] [free full text]
  11. “Apixaban versus warfarin in patients with atrial fibrillation” (ARISTOTLE). N Engl J Med. 2011 Sep 15;365(11):981-92. [post – Week 23] [free full text]
  12. “Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes” (Look AHEAD). N Engl J Med. 2013 Jul 11;369(2):145-54. [post – Week 45] [free full text]
  13. “Angiotensin-neprilysin inhibition versus enalapril in heart failure” (PARADIGM-HF). N Engl J Med. 2014 Sep 11;371(11):993-1004. [post – Week 37] [free full text]


  1. “Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial” (VERT). JAMA. 1999 Oct 13;282(14):1344-52. [post – Week 18] [free full text]
  2. “Effects of Intensive Glucose Lowering in Type 2 Diabetes” (ACCORD). N Engl J Med. 2008 Jun 12;358(24):2545-59. [post – Week 39] [free full text]
  3. “Intensive versus Conventional Glucose Control in Critically Ill Patients” (NICE-SUGAR). N Engl J Med 2009; 360:1283-1297. [post – Week 1] [free full text]


  1. “Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis.” N Engl J Med. 1999 Aug 5;341(6):403-9. [post – Week 5] [free full text]
  2. “Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.” N Engl J Med. 2000 Aug 3;343(5):310-6. [post – Week 30] [free full text]
  3. “A model to predict survival in patients with end-stage liver disease” (MELD score). Hepatology. 2001 Feb;33(2):464-70. [post – Week 10] [free full text]
  4. “Rifaximin treatment in hepatic encephalopathy.” N Engl J Med. 2010 Mar25;362(12):1071-81. [post – Week 32] [free full text]
  5. “Early use of TIPS in patients with cirrhosis and variceal bleeding.” N Engl J Med. 2010 Jun 24;362(25):2370-9. [post – Week 44] [free full text]
  6. “Transfusion strategies for acute upper gastrointestinal bleeding.” N Engl J Med. 2013 Jan 3;368(1):11-21. [post – Week 46] [free full text]
  7. “Prednisolone or pentoxifylline for alcoholic hepatitis” (STOPAH). N Engl J Med. 2015 Apr 23;372(17):1619-28. [post – Week 49] [free full text]

Hematology / Oncology

  1. “A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group” (TRICC). N Engl J Med. 1999 Feb 11;340(6):409-17. [post – Week 15] [free full text]
  2. “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer” (CLOT). N Engl J Med. 2003 Jul 10;349(2):146-53. [post – Week 25] [free full text]
  3. “Mortality results from a randomized prostate-cancer screening trial” (PLCO). N Engl J Med. 2009 Mar 26;360(13):1310-9. [post – Week 35] [free full text]
  4. “Early palliative care for patients with metastatic non-small-cell lung cancer.” N Engl J Med. 2010 Aug 19;363(8):733-42. [post – Week 12] [free full text]
  5. “Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening” (NLST). N Engl J Med. 2011 Aug 4;365(5):395-409 [post – Week 4] [free full text]
  6. “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.” (EINSTEIN-PE). N Engl J Med. 2012 Apr 5;366(14):1287-97. [post – Week 52] [free full text]

Infectious Disease

  1. “Dexamethasone in Adults With Bacterial Meningitis.” N Engl J Med 2002; 347:1549-1556
    [post – Week 3] [free full text]
  2. “Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study” (CURB-65). Thorax. 2003 May;58(5):377-82. [post – Week 13] [free full text]
  3. “A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.” Clin Infect Dis. 2007 Aug 1;45(3):302-7. [post – Week 43] [free full text]
  4. “Effect of early versus deferred antiretroviral therapy for HIV on survival.” N Engl J Med. 2009 Apr 30;360(18):1815-26. [post – Week 22] [free full text]
  5. “Duodenal infusion of donor feces for recurrent Clostridium difficile.” N Engl J Med. 2013 Jan 31;368(5):407-15. [post – Week 51] [free full text]


  1. “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes” (IDNT). N Engl J Med. 2001 Sep 20;345(12):851-60. [post – Week 42] [free full text]
  2. “Correction of anemia with epoetin alfa in chronic kidney disease.” (CHOIR). N Engl J Med. 2006 Nov 16;355(20):2085-98. [post – Week 33] [free full text]
  3. “Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status.” J Am Soc Nephrol. 2009 Sep;20(9):2075-84. [post – Week 9] [free full text]
  4. “Combined angiotensin inhibition for the treatment of diabetic nephropathy” (VA NEPHRON-D). N Engl J Med. 2013 Nov 14;369(20):1892-903. [post – Week 47] [free full text]
  5. “A controlled trial of renal denervation for resistant hypertension.” (SYMPLICITY HTN-3). N Engl J Med. 2014 Apr 10;370(15):1393-401. [post – Week 24] [free full text]

Pulmonary/Critical Care

  1. “Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome” (ARDSNet). N Engl J Med. 2000 May 4;342(18):1301-8. [post – Week 14] [free full text]
  2. “Early goal-directed therapy in the treatment of severe sepsis and septic shock.” (Rivers trial). N Engl J Med. 2001 Nov 8;345(19):1368-77. [post – Week 36] [free full text]
  3. “Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest.” N Engl J Med. 2002 Feb 21;346(8):549-56. [post – Week 21] [free full text]
  4. “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease” (TORCH). N Engl J Med. 2007 Feb 22;356(8):775-89. [post – Week 40] [free full text]
  5. “A 4-year trial of tiotropium in chronic obstructive pulmonary disease” (UPLIFT). N Engl J Med. 2008 Oct 9;359(15):1543-54. [post – Week 27] [free full text]
  6. “Hydrocortisone therapy for patients with septic shock” (CORTICUS). N Engl J Med. 2008 Jan 10;358(2):111-24. [post – Week 8] ][free full text]
  7. “Prone positioning in severe acute respiratory distress syndrome.” (PROSEVA). N Engl J Med. 2013 Jun 6;368(23):2159-68. [post – Week 17] [free full text]
  8. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)” (SEPSIS-3). JAMA. 2016 Feb 23;315(8):801-10. [post – Week 50] [free full text]


  1. “Rituximab versus Cyclophosphamide for ANCA-associated vasculitis” (RAVE). N Engl J Med. 2010 Jul 15;363(3):221-32. [post – Week 19] [free full text]


  1. “Fever of unexplained origin: report on 100 cases.” Medicine (Baltimore). 1961 Feb;40:1-30. [post – Week 7] [free full text]
  2. “Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial.” Arch Intern Med. 2002 May 27;162(10):1117-21. [post – Week 31] [free full text]
  3. “Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.” Lancet. 2008 May 31;371(9627):1839-47. [post – Week 38] [free full text]
  4. “The Oregon Experiment – Effects of Medicaid on Clinical Outcomes.” N Engl J Med. 2013 May 2;368(18):1713-22. [post – Week 26] [free full text]